Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
claire.brooks@oncology.ox.ac.uk
octo-safety@oncology.ox.ac.uk

Telephone
01865 617082

ORCID
https://orcid.org/0000-0002-3410-8971

Claire Brooks

MSc Medical Statistics

Pharmacovigilance Manager

Previously: Portfolio Lead, Radiotherapy & Imaging Trials, Patient and Public Involvement Coordinator

Recent publications

A randomised phase II multicentre study of ipilimumab with temozolomide vs temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: Ipi-Glio.

Mulholland PJ. et al, (2023), JOURNAL OF CLINICAL ONCOLOGY, 41, LBA2023 - LBA2023

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.

Brown NF. et al, (2020), BMC Cancer, 20

Cytosponge™ for post-chemoradiation surveillance of oesophageal cancer: a feasibility study.

Levy S. et al, (2019), Ann Oncol, 30 Suppl 4

Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.

Jankowski JAZ. et al, (2018), Lancet, 392, 400 - 408

Chemoprevention of Esophageal Cancer with esomeprazole and aspirin therapy: efficacy and safety in the phase III randomized factorial AspECT Trial

jankowski JJ. et al, (2018)

Sarin Exposures in A Cohort of British Military Participants in Human Experimental Research at Porton Down 1945-1987.

Keegan TJ. et al, (2017), Ann Work Expo Health, 62, 17 - 27

SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer

Virdee PS. et al, (2017)

SPARC: A Phase I trial of pre-operative, margin intensive, stereotactic body radiation therapy (SBRT) for previously untreated borderline resectable pancreatic cancer

Odondi LET. et al, (2016)

A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.

Weaver A. et al, (2014), Support Care Cancer, 22, 2677 - 2685

Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.

Nicum S. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31

Mortality in British military participants in human experimental research into chemical warfare agents at Porton Down: cohort study.

Venables KM. et al, (2009), BMJ (Clinical research ed.), 338

Cancer morbidity in British military veterans included in chemical warfare agent experiments at Porton Down: cohort study.

Carpenter LM. et al, (2009), BMJ (Clinical research ed.), 338

Mortality in british military participants in human experimental research into chemical warfare agents at Porton Down: Cohort study

Venables KM. et al, (2009), BMJ (Online), 338

Cancer morbidity in british military veterans included in chemical warfare agent experiments at porton down: Cohort study

Carpenter LM. et al, (2009), BMJ (Online), 338

Mortality in British military participants in human experimental research into chemical warfare agents at Porton Down: cohort study.

Venables KM. et al, (2009), BMJ, 338

Cancer morbidity in British military veterans included in chemical warfare agent experiments at Porton Down: cohort study.

Carpenter LM. et al, (2009), BMJ, 338

Exposures recorded for participants in the UK Chemical Warfare Agent Human Research Programme, 1941-1989.

Keegan TJ. et al, (2009), Ann Occup Hyg, 53, 83 - 97

Reconstructing exposures from the UK chemical warfare agent human research programme.

Keegan T. et al, (2007), Ann Occup Hyg, 51, 441 - 450

Symptoms, ill-health and quality of life in a support group of Porton Down veterans.

Allender S. et al, (2006), Occup Med (Lond), 56, 329 - 337

Symptoms, ill-health and quality of life in a support group of Porton Down veterans

Allender S. et al, (2006), Occupational Medicine, 56, 329 - 337